TheraRadar
← Back
Data updated: Jun 28, 2026

QILU PHARM HAINAN

Generics
OncologyCardiovascularInfectious Disease Execution: Needs Improvement

QILU PHARM HAINAN is a generic drug manufacturer focused on Oncology, Cardiovascular, Infectious Disease.

2014
Since
18
Drugs
-
Trials
2
New Drugs (2yr)

QILU PHARM HAINAN at a Glance

  • Growing R&D activity with 84 trials in last 2 years
  • Fast trial execution (10 months median completion)

QILU PHARM HAINAN's Key Drugs

QILU PHARM HAINAN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

QILU PHARM HAINAN's Recent FDA Approvals

QILU PHARM HAINAN secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections
BORTEZOMIB NDA
2024-08-26
bortezomib
1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

QILU PHARM HAINAN's Therapeutic Areas

QILU PHARM HAINAN's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 40%
4 drugs
Cardiovascular 20%
2 drugs
Infectious Disease 20%
2 drugs
Gastroenterology 10%
1 drugs
Dermatology 10%
1 drugs

QILU PHARM HAINAN's Top Competitors

QILU PHARM HAINAN's closest competitors by therapeutic-area and drug-target overlap include Baxter, Pfizer, and FOUGERA PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
FOUGERA PHARMS other
Dermatology, Oncology, Cardiovascular, Infectious Disease
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Gastroenterology

QILU PHARM HAINAN Pipeline Snapshot

Active clinical trials for QILU PHARM HAINAN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 8/46 completed
  • • Speed: 10 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges